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SHP2 Regulates the Osteogenic 
Fate of Growth Plate Hypertrophic 
Chondrocytes
Lijun Wang1, Jiahui Huang1, Douglas C. Moore1, Chunlin Zuo1,8, Qian Wu2, Liqin Xie3, Klaus 
von der Mark4, Xin Yuan5, Di Chen6, Matthew L. Warman  7, Michael G. Ehrlich1 & Wentian 
Yang1
Transdifferentiation of hypertrophic chondrocytes into bone-forming osteoblasts has been reported, 
yet the underlying molecular mechanism remains incompletely understood. SHP2 is an ubiquitously 
expressed cytoplasmic protein tyrosine phosphatase. SHP2 loss-of-function mutations in chondroid 
cells are linked to metachondromatosis in humans and mice, suggesting a crucial role for SHP2 in the 
skeleton. However, the specific role of SHP2 in skeletal cells has not been elucidated. To approach this 
question, we ablated SHP2 in collagen 2α1(Col2α1)-Cre- and collagen 10α1(Col10α1)-Cre-expressing 
cells, predominantly proliferating and hypertrophic chondrocytes, using “Cre-loxP”-mediated gene 
excision. Mice lacking SHP2 in Col2α1-Cre-expressing cells die at mid-gestation. Postnatal SHP2 
ablation in the same cell population caused dwarfism, chondrodysplasia and exostoses. In contrast, 
mice in which SHP2 was ablated in the Col10α1-Cre-expressing cells appeared normal but were 
osteopenic. Further mechanistic studies revealed that SHP2 exerted its influence partly by regulating 
the abundance of SOX9 in chondrocytes. Elevated and sustained SOX9 in SHP2-deficient hypertrophic 
chondrocytes impaired their differentiation to osteoblasts and impaired endochondral ossification. 
Our study uncovered an important role of SHP2 in bone development and cartilage homeostasis by 
influencing the osteogenic differentiation of hypertrophic chondrocytes and provided insight into the 
pathogenesis and potential treatment of skeletal diseases, such as osteopenia and osteoporosis.
Skeletal development occurs through two distinct processes: intramembranous ossification, which generates 
craniofacial bones and the lateral part of clavicles, and endochondral ossification, which produces the long bones 
of the limbs, the base of the skull, the vertebrae, the ribs and medial part of the clavicles1. Beginning with the con-
densation of undifferentiated mesenchymal cells, intramembranous ossification forms flat bones in mesenchymal 
tissue without a cartilaginous anlagen2. By contrast, during endochondral ossification, cells within the center 
of the condensation differentiate into chondrocytes that secrete extracellular matrix (ECM) rich in aggrecan 
and collagen type II (COL2α1)3,4. As endochondral ossification progresses, cells in the center of the condensa-
tion exit the cell cycle, undergo hypertrophic differentiation, and begin to produce ECM rich in collagen type X 
(COL10α1), which is calcified during skeletal development5. Terminally differentiated hypertrophic chondro-
cytes are ultimately removed from the cartilage template as the mineralized cartilage matrix is replaced by bone. 
It is well established that many of the hypertrophic chondrocytes are removed via programmed (apoptotic or 
autophagic) cell death6,7. However, there is increasing evidence that a substantial fraction of the hypertrophic 
chondrocytes in the growth plate transdifferentiate into osteoblasts that persist to produce trabecular bone and 
maintain mineral homeostasis8–10.
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The formation of the cartilage anlage, its subsequent differentiation into mature chondrocytes, and the ulti-
mate transdifferentiation of hypertrophic chondrocytes into functioning osteoblasts all depend on signals evoked 
by growth factors and other regulatory peptides11,12, though cell-cell, and cell-matrix interactions are also impor-
tant13,14. Besides producing ECM proteins, terminally differentiated hypertrophic chondrocytes release matrix 
metalloproteases, such as MMP13, MMP9, and cathepsins15–17, and growth factors (e.g. VEGF, IGF1, RANKL, 
and FGFs), which influence matrix remodeling, osteoclast precursor recruitment and subsequent osteoclastogen-
esis at the chondro-osseous front, respectively18,19. The coordinated coupling of these events is critical for skeletal 
development and longitudinal bone growth. Although the exact molecular signals controlling these processes 
remain incompletely understood, the coordinated activation of sequential signaling pathways involving FGF, 
WNT/β-CATENIN, hedgehog, and BMP have been shown to be crucial20–27. Understanding how these signaling 
pathways are regulated will provide insight into skeletal development and the treatment of disease.
SHP2, encoded by PTPN11, is a widely expressed SH2 domain-containing non-receptor protein tyrosine 
phosphatase. Its orthologs are shared by nearly all vertebrates, functioning to regulate the viability, prolifera-
tion, differentiation, and migration of a wide variety of cells28,29. Accumulating evidence suggests a crucial role 
for SHP2 in skeletal development and maintenance. In humans, SHP2 gain-of-function (GOF) mutations cause 
Noonan Syndrome (NS), whose skeletal manifestations include short stature, scoliosis, pectus malformation and 
craniofacial abnormalities (macrocephaly, oral malformation and hypertelorism)30,31. Mice bearing SHP2 GOF 
mutations are small, and have increased skull length and hypertelorism32. Hyperactivation of ERK1/2 signaling 
reportedly causes these developmental abnormalities, and inhibition of ERK1/2 can rescue the skull defects in 
mice with NS32–34. Conversely, SHP2 loss-of-function (LOF) mutations have been linked to the benign cartilage 
tumor syndrome metachondromatosis, in both humans and mice35–38. Thus, alterations in the expression of SHP2 
can be associated with both osteogenic and chondrogenic phenotypes. The specific role of SHP2 in skeletal devel-
opment and disease is an important question that has yet to be explored.
The SOX9 and WNT/β-CATENIN signaling pathways are important regulators of chondrogenesis and oste-
oblastogenesis, respectively39. SOX9, a member of the high-mobility group (HMG) DNA-binding proteins, is 
considered a master chondrogenic transcription factor. SOX9 expression commences in mesenchymal precursors 
and persists through chondrocyte hypertrophy40–42. SOX9 promotes the expression of critical chondrocytic genes, 
including Col2α1, Col10α1, Matn3 and Acan41,43, and inhibits the terminal differentiation and Vegfα expression 
of hypertrophic chondrocytes42,44. Downregulation of SOX9 in the hypertrophic layer of growth plate cartilage 
disinhibits vascular invasion and endochondral ossification42. β-CATENIN and RUNX2, on the other hand, are 
crucial for osteoblastogenesis and ossification45–48. Removal of β-CATENIN from hypertrophic chondrocytes 
impairs their osteogenic differentiation and trabecular bone formation, while sustained β-CATENIN activation 
leads to enhanced bone mineralization49. This suggests that β-CATENIN signaling is crucial for the transdiffer-
entiation of hypertrophic chondrocytes.
SHP2 has been implicated in the regulation of SOX950,51, which is an antagonist of β-CATENIN45,52. However, 
it is unknown whether the abundance and transcriptional activity of SOX9 and β-CATENIN in hypertrophic 
chondrocytes, and whether the osteogenic differentiation of hypertrophic chondrocytes, are modulated by 
SHP2. To begin addressing these questions, we generated chondrocyte-stage-specific SHP2 deficient mice. 
Characterization of the skeletal phenotype of mice lacking SHP2 in COL2α1- and COL10α1-expressing cells led 
to the discovery of SHP2 as an important regulator of chondrocyte proliferation, maturation, and differentiation 
to bone forming osteoblasts.
Results
SHP2 deletion in COL2α1- but not COL10α1-expressing cells causes dwarfism, exostoses, and 
chondrodysplasia. A “Cre-loxP”-mediated gene deletion approach was used to study the function of SHP2 
in cartilage and circumvent the embryonic lethality of global SHP2 deletion (Fig. S1)53,54. Control and SHP2 
knockout mice were generated by crossing homozygous Ptpn11 floxed (Ptpn11fl/fl) mice36 with SHP2 heterozy-
gous (Ptpn11fl/+) mice carrying Col2α1 or Col10α1 promoter-driven Cre recombinase55,56 (Fig. S1A). Breeders 
for the SHP2 ablation in chondrocytes were generated by crossing mice bearing a single Ptpn11 floxed allele 
(Ptpn11fl/+) to transgenic mice in which Cre expression is under the control of Col2α155,57 or Col10α1 promoter56. 
Deleting SHP2 in proliferating chondrocytes required tamoxifen-inducible Tg(Col2α1-CreERt2)55, since SHP2 
deletion via Tg(COL2α1-Cre)57 resulted in intrauterine death by day E11.5 (Fig. S1C,D). The final breeding strat-
egy yielded Ptpn11fl/+;Tg(Col2α1-CreERT2), Ptpn11fl/fl;Tg(Col2α1-CreERT2), Ptpn11fl/+;Tg(Col10α1-Cre), and 
Ptpn11fl/fl;Tg(Col10α1-Cre) compound mice, abbreviated as SHP2Col2α1ERCTR, SHP2Col2α1ERKO, SHP2Col10α1CTR, 
and SHP2Col10α1KO, respectively (Fig. S1B). Tg(Col2α1-CreERT2) and Tg(Col10α1-Cre) mice express a func-
tional Cre in COL2α1- and COL10α1-expressing chondrocytes as revealed by Rosa26LacZ (R26lacZ) reporter58 
(Fig. S2A–C).
Age- and sex-matched SHP2Col2α1ERCTR and SHP2Col2α1ERKO mice received three doses of tamoxifen (TM) 
at the end of postnatal week 2 and cohorts of animals from SHP2Col2α1ERCTR, SHP2Col2α1ERKO, SHP2Col10α1CTR 
and SHP2Col10α1KO strains were euthanized at weeks 6, 8 and 10 for skeletal development evaluation. By 8 
weeks SHP2Col2α1ERKO mice were significantly smaller (−17%) than the corresponding SHP2Col2α1ERCTR mice 
(13.63 ± 0.48 cm vs. 16.38 ± 0.75 cm, n = 4) (Fig. 1Ai,ii; Fig. S3A). Other features of the skeletal phenotype in 
adult SHP2Col2α1ERKO mice included scoliosis, small rib cages, and multiple joint dysplasias affecting the phalan-
ges, metatarsals, knees, hips, vertebrae and chondrocostal junctions (Fig. 1Ai–x,Bi–iv). Micro-CT (µ-CT) and 
x-ray imaging revealed the existence of exostoses at the knees and hips, deformed pelvises, shallow acetabulums 
and misshapen femoral heads and greater trochanters (Fig. 1Bi–iv and Fig. 2D). Of note, the bone mineral density 
in the SHP2Col2α1ERKO mice was reduced compared to sex- and age-matched SHP2Col2α1ERCTR mice (Fig. 1Aix,x), 
and the growth plates in the caudal vertebrae (Fig. 1Av,vi, arrows) and other tubular bones of the SHP2Col2α1ERKO 
mice were much wider than those of the SHP2Col2α1ERCTR mice. Similar morphological analysis was performed 
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on the SHP2Col10α1KO and SHP2Col10α1CTR mice. In contrast to the SHP2Col2α1ERKO mice, there were no gross 
skeletal defects in the SHP2Col10α1KO mice through 10 weeks of age. However, the SHP2Col10α1KO mice did 
exhibit the same apparent reduction in bone mineralization compared to corresponding sex- and age-matched 
SHP2Col2α1ERCTR mice (Fig. S3B).
Taken together, these data suggest that functional SHP2 is crucial for normal cartilage development and bone 
mineralization in COL2α1-expressing chondrocytes, but that it only influences bone mineral homeostasis in 
COL10α1-expressing chondrocytes.
Cartilage and bone development require SHP2. Having established the importance of SHP2 in both 
cartilage and bone development, we sought to explore the cellular mechanisms by which SHP2 regulates skele-
togenesis. To start, knee joints from TM-treated 6- and 8-week-old SHP2Col2α1ERCTR and SHP2Col2α1ERKO mice 
were harvested and examined histologically. By 6 weeks of age the SHP2Col2α1ERCTR mice had well-organized 
growth plates and articular cartilage stained strongly positive for proteoglycan (Fig. 2Ai,iii,v). In contrast, the 
columnar structure of the growth plate cartilage in the SHP2Col2α1ERKO mice was dysregulated, featuring sig-
nificantly expanded proliferating and hypertrophic zones (Fig. 2Aii,iv; Fig. S4A). Similar morphologic changes 
were observed in SHP2Col2α1ERKO mice bearing a R26mTG reporter (Fig. S4B). These drastic changes in the growth 
plate cartilage of SHP2Col2α1ERKO mice were not observed in SHP2Col10α1KO mice, which had normal-appearing 
cartilage with the exception of a slight increase in height of the hypertrophic layer of chondrocytes at 8 weeks 
(Fig. 2B). Surprisingly, the articular cartilage in the knee joints in the SHP2Col2α1ERKO, SHP2Col10α1KO, and litter-
mate control mice were comparable at 6 and 8 weeks of age. (Fig. 2Av,vi; Bv,vi and Fig. S4Biii,iv), though the adult 
SHP2Col2α1ERKO mice developed exostoses and enchondromas at the metaphyseal regions of the long bones and 
vertebrae (Fig. 2C and D).
To investigate whether SHP2 was required for cell proliferation in COL2α1-expressing physeal cartilage cells 
as it is in many other cell types28,29, pregnant females that had received 2 doses of TM injections at embryonic 
(E) day 13.5 and E15.5 were administered one dose of 5-ethynyl-2-deoxyuridine (EdU) at E16.5, and sacrificed 
at E17.5 to collect embryos. EdU staining of tibia frozen sections from these mice revealed an increased number 
of EdU+ cells in SHP2Col2α1ERKO mice, compared to SHP2Col2α1ERCTR mice, indicating that SHP2 deletion in 
COL2α1-expressing cells promoted EdU uptake and that under normal condition SHP2 functions as a negative 
regulator of chondrocyte proliferation (Fig. S4C).
Given the apparent reduction in x-ray bone mineral density in the COL2α1+ and COL10α1+ cell-specific 
SHP2 knockout mice, we performed histomorphometric analysis on von Kossa-stained femoral sections from 
Figure 1. Mice with SHP2 deletion in COL2α1- and COL10α1-expressing cells have osteopenia, and SHP2 
deletion in COL2α1- but not COL10α1-expressing chondrocytes causes dwarfism, exostoses, and multiple 
joint dysplasia. (A) X-ray images demonstrate dwarfism and scoliosis (i, ii), and chondrodysplasia of the 
metatarsophalangeal joints (iii, iv), caudal vertebrae (v, vi), hip (vii, viii) and knee joints (ix, x) in 8-week-old 
SHP2Col2α1ERKO mice, compared to age and sex-matched SHP2Col2α1ERCTR mice. Note that SHP2Col2α1ERKO 
mice exhibited slightly reduced bone mineral density, exostoses, and a broadened growth plate cartilage in 
the caudal vertebrae (v, vi, bars and arrows). (B) Representative µ-CT images show the shallow acetabular 
sockets, misshapen femoral heads and greater trochanters (i, ii) and exostoses (iii, iv) in SHP2Col2α1ERKO mice, 
compared to SHP2Col2α1ERCTR mice. (C) X-ray images demonstrate comparable morphology in 10-week-old 
SHP2Col10α1CTR and SHP2Col10α1KO mice. Note the slight decrease in bone mineral density in SHP2Col10α1KO 
mice compared to SHP2Col10α1CTR controls (n = 4).
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10-week-old SHP2Col2α1ERKO and SHP2Col10α1KO mice. SHP2 deletion in both knockout strains was associated 
with a significant reduction of calcified trabecular bone compared to age- and sex-matched controls (Fig. 3A). 
These observations were generally supported by microcomputed tomographic analysis (μCT), which revealed 
significant decreases in volumetric density (bone volume/total volume or BV/TV) and trabecular thickness (Tb.
th.) in SHP2Col2α1ERKO and SHP2Col10α1KO mice compared to their corresponding controls (SHP2Col2α1ERCTR and 
SHP2Col10α1CTR, respectively) (Fig. 3B). The structure model index (SMI) increased in the SHP2Col2α1ERKO mice. 
Trabecular number (Tb.N), space (Tb.S), and connectivity density (conn dens) were not significantly affected at 
this time point. Collectively, the histology, cell proliferation, and morphometric results demonstrate that SHP2 
has a developmental stage-specific role in chondrogenesis and that SHP2 regulates bone mineral homeostasis in 
SHP2Col2α1ERKO and SHP2Col10α1KO through its effect on chondroid cells.
SHP2 regulates the osteogenic differentiation of growth plate hypertrophic chondro-
cytes. The transdifferentiation of COL10α1+ growth plate chondrocytes into osteoblasts and osteocytes has 
been reported8–10 and has now been established as a process crucial for endochondral ossification and mineral 
homeostasis49,59. Our observation that mineralization was reduced in mice lacking SHP2 in Col10α1-expressing 
chondrocytes (radiographically and via μCT) prompted us to investigate whether SHP2 might influence the dif-
ferentiation of hypertrophic chondrocytes into osteoblasts. To start, we performed fluorescent reporter-based 
cell lineage tracing using SHP2Col10α1CTR;R26ZsG and SHP2Col10α1KO;R26ZsG mice crossed to Sp7mCherry reporter 
mice60 (SHP2Col10α1CTR;R26ZsG;Sp7mCherry and SHP2Col10α1KO;R26ZsG;Sp7mCherry, respectively). In these mice 
COL10α1(R26ZsG)-positive cells fluoresce green, OSTERIX (SP7mCherry)-positive cells fluoresce red, and 
COL10α1(R26ZsG)/OSTERIX(Sp7mCherry)-double positive cells fluoresce yellow. Yellow fluorescence identifies 
cells of COL10α1-expressing origin that subsequently began expressing OSTERIX, and thus were capable of 
participating in osteoblastogenesis and endochondral ossification.
Frozen sections from P0.5 day-old pups revealed COL10α1+/OSTERIX+ double positive (yel-
low) cells in the developing metaphyseal cancellous bone of both SHP2Col10α1CTR;R26ZsG;Sp7mCherry and 
SHP2Col10α1KO;R26ZsG;Sp7mCherry mice, but not in the growth plate and articular cartilage. Importantly, there were 
Figure 2. SHP2 modulates the proliferation and hypertrophic differentiation of growth plate chondrocytes. (A) 
Representative images of mouse knee joint coronal sections stained with Safranin O/fast green demonstrating 
broad, disorganized growth plate cartilage, affecting both proliferating (P) and hypertrophic (H) chondrocytes 
(double arrow lines) in 6-week-old SHP2Col2α1ERKO mice compared to SHP2Col2α1ERCTR mice. SHP2Col2α1ERKO 
and SHP2Col2α1ERCTR mice received TM injection at the end of week 2. Note that the articular cartilage in 
the SHP2Col2α1ERCTR and SHP2Col2α1ERKO mice is grossly similar at this age. Images iii to vi are enlarged 
views of the color-bounded  areas in images i and ii. n = 4. (B) Images of 8-week-old mouse proximal tibia 
sections stained with H&E, Safranin O/fast green demonstrating comparable growth plate and articular 
cartilage morphology in SHP2Col10α1CTR and SHP2Col10α1KO mice (n = 5). (C) Images of vertebral sections 
stained with Safranin O demonstrate enchondromas (arrows) developed in 10-week-old SHP2Col2α1ERKO 
mice (SHP2Col2α1ERCTR served as controls). Both mice received TM injection at the end of week 2 (n = 5). 
(D) Representative x-ray images of femur and tibia harvested from 10-week-old SHP2Col2a1ERKO mice 
demonstrating exostoses in the proximal femur and an enchondroma in the tibia (arrow) (n = 5).
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fewer, sparsely scattered COL10α1+/OSTERIX+ double positive cells in the SHP2Col10α1KO;R26ZsG; Sp7mCherry 
mice compared to the SHP2Col10α1CTR;R26ZsG;Sp7mCherry controls (mean± stdv of percentage: 56.75 ± 10.58 vs. 
43.17 ± 13.05. *p < 0.05, Student’s t test) (Fig. 4 A–C). Similar results were seen in P9.5 SHP2Col10α1CTR;R26mTG 
and SHP2Col10α1KO; R26mTG newborns. Intriguingly, GFP+ cells accumulated in the hypertrophic layer of growth 
plate cartilage in SHP2Col10α1KO;R26mTG mice (Fig. S5). Collectively, our cell lineage tracing studies suggest that 
SHP2 plays an important role in regulating the differentiation of terminal hypertrophic chondrocytes into oste-
oblasts, primarily affecting the metaphyseal trabecular bone formation; it has minimal effect on cortical bone.
SHP2 deletion in COL10α1-expressing hypertrophic chondrocytes promotes chondrocytic 
but represses osteogenic gene expression. After establishing that SHP2 influences the osteogenic 
differentiation of hypertrophic chondrocytes, we next investigated SHP2-related changes in gene and protein 
expression. To do so, we examined the effect of SHP2 deletion on osteogenic and chondrogenic marker expres-
sion in Col10α1-expressing chondrocytes using in situ hybridization and immunohistochemistry. We found 
that Col2α1 was upregulated in the metaphyseal region of the tibias from P1.5 SHP2Col10α1KO;R26mTG mice 
compared to SHP2Col10α1CTR;R26mTG controls, and that the osteogenic genes Ibsp, Mmp13, Runx2, and Ctnnb1 
were all down-regulated (Fig. 5). Staining of sections from P1.5 newborns revealed that SOX9 protein was sig-
nificantly increased in the hypertrophic chondrocytes of SHP2Col10α1KO mice (Fig. 6A, red bar; Fig. S9), and 
that the transcript for Sox9 was increased in the upper hypertrophic chondrocytes (Fig. 6B). Both Sox9 and 
SOX9 were expressed in similar quantities in the physeal proliferating chondrocytes in the SHP2Col10a1CTR and 
SHP2Col10a1KO mice (Fig. 6A,B). Immunostaining for β-CATENIN was non-informative as the protein levels were 
sufficiently low that they were beyond detection.
To corroborate our in situ and immunostaining data, we sought further validation of the regulation of SOX9 
and chondrocyte gene expression by SHP2 in vitro. We were forced to use proliferating rather than hypertrophic 
chondrocytes for this signaling study due to the technical difficulty of obtaining homogenous populations of 
hypertrophic chondrocytes. To do so, we established ribcage chondrocyte cell lines that expressed either normal 
(SHP2WT) or reduced (SHP2KD) levels of SHP2 (via shRNA against murine SHP2) that could be induced (or 
not) to ablate SOX9 expression by tamoxifen administration (SOX9cKO and SOX9WT). Our nomenclature for the 
cell lines was SHP2WTSOX9WT, SHP2WTSOX9cKO, SHP2KDSOX9WT, and SHP2KDSOX9cKO for the wild type, SOX9 
conditional knockout, SHP2 knockdown, and dual SHP2 knockdown/SOX9 conditional knockout, respectively 
Figure 3. SHP2 deletion in COL2α1- and COL10α1-expressing cells compromised endochondral ossification. 
(A) Representative images of von Kossa/Fast red stained mouse femoral sections demonstrating a reduction 
of cancellous bones in 10-week-old SHP2Col2α1ERKO and SHP2Col10α1KO mice, compared to SHP2Col2α1ERCTR 
and SHP2Col10α1CTR mice. Mineralized bone was segmented from an 800 µm × 1200 µm rectangular region 
interested below the growth plate cartilage and quantified using NIH ImageJ software (n = 4, *p < 0.05, 
Student’s t test). (B) µ-CT analysis of proximal tibia morphology demonstrating reduced BV/TV and Tb.Th in 
10-week-old SHP2Col2α1ERKO and SHP2Col10α1KO mice, compared to SHP2Col2α1ERCTR and SHP2Col10α1CTR 
controls (n = 4, *p < 0.05, Student’s t test). BV/TV: bone volume/total volume; Tb.Th: trabeculae thickness; 
Tb.N: trabeculae number; Tb.Sp: trabecule space; Conn.Dens: connectivity density; SMI: Structure model 
index.
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Figure 4. SHP2 deletion in COL10α1-expressing chondrocytes arrests their osteogenic differentiation. (A) 
Representative fluorescent images of mouse tibia sections demonstrating the abundance and distribution of 
COL10α1-expressing chondrocytes (ZsG+), OSTERIX+ osteoblasts (RFP+) and osteoblasts derived from 
COL10α1-expressing chondrocytes (ZsG+/RFP+, yellow) in P0.5-day-old SHP2Col10α1CTR;R26ZsG;Sp7mCherry 
and SHP2Col10α1KO;R26ZsG;Sp7mCherry mice (n = 3). (B) Enlarged views of the corresponding boxed areas in 
A demonstrating the reduction of ZsG+/RFP+ double positive (yellow) cells on trabecular bone surfaces 
in SHP2Col10α1KO;R26ZsG;Sp7mCherry mice, compared to SHP2Col10α1CTR;R26ZsG;Sp7mCherry controls (n = 3). 
The scale bar on the right is 500 µm. Only cells within the 500 µm × 50 µm rectangular region of interest were 
counted. (C) Bar graphs depicting the number of COL10α1+-cell-derived osteoblasts. SHP2 deletion in 
COL10a1-expressing chondrocytes compromised their osteogenic differentiation, compared to the controls 
(n = 3, *p < 0.05, Student’s t test).
Figure 5. SHP2 deletion in COL10α1-expressing chondrocytes sustains the expression of chondrocytic but 
represses the expression of osteogenic genes. (A) Representative images of P0.5-day-old mouse tibia sections 
hybridized in situ with the probes indicated to assess the abundance of gene transcripts. (B) Enlarged views of 
corresponding boxed areas in A. (C) Bar graphs demonstrating an increase of Col2α1 and a decrease of Ibsp, 
Mmp13, Runx2 and Ctnnb1 in the SHP2Col10α1KO; R26mTG mice, compared to the controls (n = 3, *p < 0.05, 
**p < 0.01, and ***p < 0.001, Student’s t test.). Scale bar:100 µm.
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(Fig. S7A,B). SOX9 knockout was effected by 96 hours of exposure to 4-OH tamoxifen (TM) to induce Sox9 dele-
tion, and total cell lysates were analyzed by western blotting and total RNA was used for qRT-PCR.
SOX9 was robustly deleted upon TM treatment and SHP2 was effectively knocked down by the shRNA 
(Figs 6C; S10). As anticipated, the transcript level for the chondrocytic genes Acan and Col10α1 decreased 
significantly in the tamoxifen-mediated SOX9 deleted SHP2KDSOX9cKO and SHP2WTSOX9cKO chondrocytes 
(Fig. 6D). Importantly, the abundance of both SOX9 and the transcripts for the chondrocytic genes Acan and 
Col10α1 increased significantly in the SHP2KDSOX9WT chondrocytes compared to the SHP2WTSOX9WT controls 
(Fig. 6C,D), providing compelling evidence that SHP2 modifies Acan and Col10α1 expression via SOX9. Similar 
results were also obtained on E17.5 embryos in which SHP2 was deleted in COL2α1-expressing cells (Fig. S6).
Figure 6. SHP2 deletion in hypertrophic chondrocytes increases SOX9 abundance and reducing Sox9 in 
hypertrophic chondrocytes restores osteogenic gene expression in SHP2Col10α1KO mice. (A) Representative 
images of P1.5 mouse tibia sections immunostained with SOX9 antibody (left), with enlarged views of the 
boxed areas (middle). Quantification of SOX9 expression in hypertrophic chondrocytes is shown on the right. 
SOX9 expression was elevated in the hypertrophic chondrocytes of SHP2Col10α1KO (KO) mice, compared 
to SHP2Col10α1CTR (CTR). (n = 3, **p < 0.01, Student’s t test). (B) Images of the proximal tibia sections 
demonstrating the abundance of Sox9 in P0.5 SHP2Col10α1CTR and SHP2Col10α1KO mice. In situ hybridization 
was carried out using RNAscope technology. Transcript abundance was visualized by DAB staining of HRP-
conjugated DNA probes. Note that the height of the hypertrophic zone was increased in SHP2Col10α1KO mice, 
accompanied by an expansion of the Sox9-expressing top layer (between doted lines) of the hypertrophic zone. 
Expression of Sox9 and SOX9 was comparable in proliferating chondrocytes between SHP2Col10α1CTR and 
SHP2Col10α1KO mice, n = 3. (C) Western blots (left) and bar graphs (right) demonstrating the expression of 
SHP2 and SOX9 in immortalized SHP2WTSOX9WT, SHP2WTSOX9cKO, SHP2KDSOX9WT and SHP2KDSOX9cKO 
chondrocytes (See Supplementary Fig. 10 for the full-length blots). SHP2 was efficiently knocked down in 
SHP2KDSOX9WT and SHP2KDSOX9cKO chondrocytes, and SOX9 was robustly deleted in SHP2WTSOX9cKO and 
SHP2KDSOX9cKO chondrocytes with tamoxifen treatment. Importantly, SHP2 knockdown in SHP2KDSOX9WT 
cells significantly increases the level of SOX9. Note that SHP2 was markedly knocked down in SHP2KDSOX9WT 
and SHP2KDSOX9cKO chondrocytes and SOX9 was robustly deleted in SHP2WTSOX9cKO and SHP2KDSOX9cKO 
chondrocytes upon TM treatment. Importantly SHP2 knockdown in SHP2KDSOX9WT chondrocytes 
significantly increased SOX9 abundance (red arrow) (*p < 0.05, Student’s t test; n = 3). (D) qRT-PCR data show 
the increased transcript abundance of chondrocytic genes Acan and Col10α1 in SHP2KDSOX9WT chondrocytes 
in which SOX9 was upregulated upon SHP2 knockdown. SHP2WTSOX9WT chondrocytes served as controls. 
Note that the elevated abundance of Acan and Col10α1 in SHP2KDSOX9WT chondrocytes was rescued by SOX9 
deletion in SHP2KDSOX9cKO chondrocytes (n = 3, *p < 0.05, Student’s t test).
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Taken together, our cell lineage tracing and in situ hybridization studies suggest that SHP2 influences oste-
oblastogenesis and endochondral ossification, at least in part, by promoting the differentiation of hypertrophic 
chondrocytes into osteoblasts, and that SHP2 modulates the osteogenic differentiation of hypertrophic chondro-
cytes by indirectly influencing the expression and activity of osteogenic transcription factors via SOX9.
Haploinsufficiency of Sox9 rescues the osteogenic differentiation of hypertrophic chondrocytes 
in SHP2Col10α1KO mice. To confirm our finding that SHP2 acts through SOX9 to modulate the osteogenic 
differentiation of hypertrophic chondrocytes, we carried out a genetic rescue experiment in which Sox9 haplo-
insufficiency would offset the chondrogenic effect of SHP2 deletion. Sox9 wild type (Sox9+/+) and heterozygous 
Sox9 floxed mice (Sox9fl/+) were crossed to SHP2Col10α1CTR;R26ZsG and SHP2Col10α1KO;R26ZsG mice, to yield mice 
in which both SHP2 and Sox9 were modulated in Col10α1-expressing cells. Characterization of the mice in which 
Sox9 was halved in the hypertrophic chondrocytes demonstrated that the transcript levels for the osteogenic 
genes Ctnnb1, Ibsp and Mmp13, were significantly increased (in situ hybridization and quantification using NIH 
ImageJ), as were the number of GFP+ cells in the metaphyseal cancellous bone (Fig. S8). Presumably these GFP+ 
cells are osteoblasts that had transdifferentiated from hypertrophic chondrocytes labeled with the R26ZsG reporter. 
Lineage tracing using tibias from P0.5 newborns showed that loss of one allele of Sox9 did not significantly affect 
the number of ZsGreen+ cells (Fig. S8A top) or/and the abundance of osteogenic gene transcripts, Ctnnb1, Ibsp, 
and Mmp13 (Fig. S8B top) in the metaphyseal cancellous bone of the SHP2Col10α1CTR;SOX9fl/+;R26ZsG mice com-
pared to SHP2Col10α1CTR;SOX9+/+;R26ZsG controls. In contrast, both the number of ZsGeen+ cells (Fig. S8 bot-
tom) and the abundance of osteogenic marker genes markedly increased in the corresponding regions of the 
SHP2Col10α1KO;SOX9fl/+;R26ZsG mice, compared to SHP2Col10α1KO;SOX9+/+;R26ZsG controls (Fig. 7B, bottom, S8 
bottom). Collectively these data provide convincing evidence that SHP2 regulates osteogenic differentiation in 
the primary spongiosa, a process that has been shown to include transdifferentiation of hypertrophic chondro-
cytes. Importantly, they also show that this regulation is mediated in part by SOX9.
Figure 7. Haploinsufficiency of Sox9 in SHP2 deficient hypertrophic chondrocytes restores osteogenic 
marker gene expression. (A) Representative images of P1.5 mouse tibia frozen sections hybridized in situ 
to the probes indicated demonstrating the abundance of Ctnnb1, Ibsp, and Mmp13. The expression of 
Ctnnb1, Ibsp, and Mmp13 was reduced in SHP2Col10α1KO;Sox9+/+ (SHP2−SOX9+) mice, compared to 
SHP2Col10α1CTR;Sox9+/+ (SHP2+ SOX9+) controls. Removal of one allele of Sox9 from the hypertrophic 
chondrocytes in SHP2Col10a1KO;Sox9+/− mice (SHP2−SOX9−) restored the expression of Ctnnb1, Ibsp, and 
Mmp13 comparable to SHP2+ SOX9 + controls. (B) In situ hybridization data quantified using NIH ImageJ. 
n = 3, **p < 0.01, Student’s t test. (C) Diagram depicting the working model by which SHP2 modifies the 
signals evoked by receptor tyrosine kinases (RTK), extracellular matrix proteins (ECM) and cytokines, and the 
expression of SOX9 and β-CATENIN. Tilting the expression of SOX9 and β-CATENIN in the hypertrophic 
chondrocytes due to SHP2 deletion favors chondrogenic but represses osteogenic differentiation. S:Serine, 
Y:Tyrosine.
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Discussion
SHP2 is ubiquitously expressed, but little is known about its function in the skeletal system. Recently SHP2 
loss-of-function mutations have been linked to the cartilage tumor syndrome metachondromatosis35–38 and 
scoliosis37, suggesting a crucial role for SHP2 in the skeleton. To further study the role of SHP2 in cartilage, 
we adopted a genetic loss of function approach and ablated SHP2 expression in COL2α1+ (proliferating) and 
COL10α1+ (hypertrophic) chondrocytes respectively in mice. Phenotypic characterization showed that mice 
lacking SHP2 in the hypertrophic chondrocytes appeared normal through 10 weeks of age with the exception 
of a slight decrease in bone mineral density. In contrast, mice deficient SHP2 in the proliferating chondrocytes 
had a drastic skeletal phenotype. Developmental SHP2 deletion in COL2α1+ chondrocytes caused midgestation 
lethality (around E11.5), but postnatal SHP2 deletion in the same cell population led to scoliosis, expansion of 
the growth plate cartilage affecting both proliferating and hypertrophic chondrocytes, chondrodysplasia, enchon-
dromas, exostoses, and reduced bone mineral density. These findings are consistent with published work showing 
the formation of scoliosis and enchondroma-like lesions on the vertebrae of SHP2Col2α1ERKO mice and altered 
chondrocyte maturation and disorganized vertebral growth plates37,50. The distinct bone and cartilage phenotypes 
in the mice lacking SHP2 in proliferating and hypertrophic chondrocytes suggest that SHP2 has a developmental 
stage-specific role in chondrogenesis and bone mineral homeostasis and that the cellular signaling networks 
wired in the proliferating and hypertrophic chondrocytes are complex.
It’s not surprising that SHP2 deletion in COL2α1-expressing cells during development caused embryonic 
lethality in mice. It’s well known that SHP2 is essential for early embryogenesis and for multiple organs/tissues 
development53,54; Col2α1 promoter is reportedly active not only in chondroid cells, but also in the mesenchyme 
of the frontal nasal mass, spinal neural tube, and the most ventral and dorsal parts of the forebrain during early 
embryogenesis61–63. The midgestation lethality of SHP2Col2α1KO mice and the survival of mice with postnatal 
SHP2 deletion in the COL2α1-expressing cells suggest that the lethality likely resulted from SHP2 deletion in 
COL2α1+ non-chondroid cells.
Although the transdifferentiation of hypertrophic chondrocytes into osteoblasts8–10 and their involvement in 
endochondral ossification and mineral homeostasis have been reported49,59, the molecular mechanism(s) that 
regulates this process remains incompletely understood. Our data suggest that SHP2 is a key regulator for the 
osteogenic differentiation of hypertrophic chondrocytes. Mice deficient in SHP2 in COL10α1+ chondrocytes 
had a reduction of bone mineral density, BV/TV and Tb.Th, and an increased layer of hypertrophic chondrocytes 
within the growth plate. Indeed, our cell lineage tracing studies revealed that SHP2 deletion in COL10α1+ chon-
drocytes significantly decreased the number of osteoblasts marked by both Col10α1-Cre;R26ZsG and Sp7mCherry 
dual reporters in the cancellous bone region, which was accompanied by a reduction of osteogenic marker gene 
transcripts Ibsp, Runx2 and Ctnnb1. Collectively these data indicate that SHP2 is a key regulator for the differen-
tiation of hypertrophic chondrocytes into osteoblasts.
Commitment of condensed mesenchymal cells into chondrocytes and osteoblasts requires several fate 
decisions, which are modified by multiple signaling pathways and transcription factors, including SOX9 and 
β-CATENIN39–42. SOX9 is one of the earliest makers for mesenchymal condensation and for the commitment of 
mesenchymal progenitors to osteochondroprogenitors43. With the progression of skeletal development, SOX9 
is mainly restricted to the epiphyseal proliferating chondrocytes, maintains chondrocyte columnar prolifera-
tion41,43 and drives cell hypertrophy42. Although SOX9 persists after Sox9 expression ceases in the hypertrophic 
chondrocytes in the growth plate, it was reported that Sox9 is expressed in the upper layer of the COL10α1+ 
hypertrophic zone42. In hypertrophic chondrocytes, SOX9 keeps β-CATENIN in check and inhibits osteoblas-
tic differentiation42. Conversely β-CATENIN promotes the osteogenic commitment of osteochondroprogeni-
tors39,52,64 and hypertrophic chondrocytes; deletion of β-CATENIN in COL10α1+ cells impairs trabecular bone 
formation49,59,65. Importantly, SOX9 and β-CATENIN reciprocally regulate one another in an antagonistic man-
ner. Disrupting the balance of SOX9 and β-CATENIN signaling in skeletal cells modifies the chondrogenic or 
osteogenic fate decision45,66,67.
We examined the effect of SHP2 deletion in COL10+ chondrocytes via the expression of SOX9, β-CATENIN, 
Sox9 and Ctnnb1. Although β-CATENIN and Ctnnb1 were below the level of detection in these cells, SOX9 and 
Sox9 was significantly upregulated in the hypertrophic zone and in the upper layer of the hypertrophic zone, 
respectively. Given that β-CATENIN signaling is essential for the osteogenic differentiation of hypertrophic 
chondrocytes and the reciprocally antagonistic regulatory relationship of β-CATENIN and SOX9, we therefore 
proposed a model (Fig. 7C) wherein SHP2 regulates the osteogenic differentiation of hypertrophic chondrocytes 
by balancing SOX9 and β-CATENIN signaling. This model is supported by the results of our rescue experiment, 
where removal of one allele of Sox9 in the SHP2 deficient hypertrophic chondrocytes restored the expression 
of osteogenic marker genes Ctnnb1 and Ibsp. However, this experiment didn’t exclude the possibility that the 
increase of SOX9 is due to the reduction of β-CATENIN as the consequence of SHP2 deletion in COL10α1+ 
chondrocytes. Indeed, SHP2 is reported to regulate the tyrosyl phosphorylation of β-CATENIN and its stability 
in other types of cells68. The work of evaluating how SHP2 regulates the expression of SOX9 and β-CATENIN in 
chondrocytes is ongoing in our laboratory.
The distinct skeletal phenotypes in mice lacking SHP2 in the COL2α1- and COL10α1-expressing cells suggest 
that SHP2 has a development-stage-specific effect in chondrogenesis. Proliferating and hypertrophic chondro-
cytes are distinct in several aspects. First, the proliferation potential of chondrocytes markedly declines when 
they gradually transition from the proliferating to the hypertrophic stage. And second, this morphological switch 
is accompanied by the qualitative and quantitative change of gene expression profiles, which affect certain lig-
ands69,70, receptors71,72, extracellular matrix proteins and transcription factors. Some of them or their downstream 
effectors may serve as the target of SHP236,66,73. This may explain why the phenotypic outcomes are different in 
mice with SHP2 ablation in the COL2α1- and COL10α1-expressing cells73–75.
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The etiology of enchondromas and exostoses, common benign cartilaginous lesions, remain elusive. 
Anatomically, exostoses and enchondromas arise adjacent to the growth plate cartilage and resemble it morpho-
logically. This suggests that growth plate chondrocytes may be candidate cells-of-origin and that dysregulation 
of cellular signaling pathways that modulate growth plate chondrocytes could contribute to the pathogenesis of 
these lesions76. The findings from this study support these views. Mice with SHP2 deletion in COL2α1+ chondro-
cytes grew exostoses and enchondromas at the metaphysis of the long bones, affecting hip, tibia, phalanges and 
vertebrae; chondrocytes with SHP2 knockout or knockdown had an elevated cell proliferation and chondrocytic 
gene expression. Most importantly, SHP2 knockout or knockdown in chondrocytes in vivo and in vitro signifi-
cantly increases the expression of SOX9, a master chondrogenic transcription factor43,77 that has also been shown 
as the driving force of tumorigeneses in multiple organs and tissues78–80. Our results and published work indicate 
that SHP2 normally represses the proliferation and/or maturation of chondrocytes, functioning as a tumor sup-
pressor in cartilage. However, SHP2 is historically considered as an oncogene and essential for the development 
and/or homeostasis of multiple organs and tissues28,29. The double-edged sword effect of SHP2 (tumorigenic and 
anti-tumorigenic) in different types of cells reflects the complexity of cellular signaling networks and the particu-
lar “wiring” of the signaling pathways therein.
In sum, we found that SHP2 regulates the differentiation of hypertrophic chondrocytes to an osteoblastic 
fate, a transition that is critical for endochondral bone formation, bone mineral and cartilage homeostasis. Our 
study also illustrates an important role for SHP2 in the embryonic and postnatal cartilage development. Its effect 
on osteogenesis is mediated by SOX9-mediated β-CATENIN signaling. Therefore, manipulating SHP2 and 
SHP2-regulated signaling pathways can potentially facilitate the development of novel therapeutics to treat carti-
lage and bone developmental and degenerative diseases.
Methods
Animals. Ptpn11 floxed (Ptpn11fl/+)36, Sox9 floxed (Sox9fl/+)41,81, Tg(Col2α1-Cre)57, Tg(Col2α1-CreERT2)55, 
Tg(Col10α1-Cre)56, Tg(CMV-CreERT2)82, Tg(Sp7/mCherry) (Sp7mCherry)60, Rosa26lacZ (R26lacZ)58, Rosa26ZsG 
(R26ZsG)83 and Rosa26mTmG (R26mTG)84 mice were reported previously. PCR genotyping conditions for Ptpn11fl and 
Sox9fl alleles, R26lacZ and R26mTG reporters and Cre transgenes have been described in the original publications 
and are available upon request. To delete SHP2 in chondrocytes that express collagen type II, alpha-1 (COL2α1) 
and type X, alpha-1 (COL10α1), a Ptpn11 floxed allele was interbred to Tg(Col2α1-Cre), Tg(Col2α1-CreERT2) and 
Tg(Col10α1-Cre) mice to generate offspring with the following nomenclature: SHP2Col2α1CTR, SHP2Col2α1KO, 
SHP2Col2α1ERCTR, SHP2Col2α1ERKO, SHP2Col10α1CTR, and SHP2Col10α1KO, respectively (Fig. S1A,B). To delete 
SOX9 in chondrocytes in vitro, a Sox9 floxed allele was interbred to Tg(CMV-CreERT2) mice to generate Sox9fl/
fl and Sox9fl/fl;Tg(CMV-CreERT2) offspring, abbreviated respectively as SOX9WT and SOX9cKO mice (Fig. S7). To 
trace COL2α1 and COL10α1-expressing cells in vivo, SHP2Col2α1ERCTR, SHP2Col2α1ERKO, SHP2Col10α1CTR and 
SHP2Col10α1KO mice were also bred with R26lacZ or R26mTG reporters, respectively. R26mTG reporter expresses fluo-
rescent protein Tomato Red ubiquitously before Cre recombination and GFP following recombination. To induce 
Tg(Col2α1-CreER) activity, 4-OH tamoxifen (TM; Sigma, MO) was dissolved in DMSO-ethanol-corn oil (4:6:90) 
mixture at a concentration of 10 mg/mL and injected intraperitoneally into SHP2Col2α1ERCTR, SHP2Col2α1ERKO 
mice (1 mg/per mouse/each dose)55,85. All transgenic mice were maintained on C57BL/6 J background.
Control and SHP2 mutant animals were sacrificed at the indicated time points and used for x-ray, histological, 
biochemical and biological analyses. All animal work was reviewed and approved by the Rhode Island Hospital 
Institutional Animal Care and Use Committee (Assurance No. A3922-01) and performed in accordance with 
PHS policy on the humane care and use of laboratory animals.
Chondrocyte isolation and cultures. Primary chondrocytes were derived from 1- to 3-day-old pups with 
modified procedures86. Briefly, the ventral parts of the rib cages from newborn mice were collected and incubated 
with trypsin-EDTA (0.25%, Invitrogen) for 1 hour at 37 °C. After washing with PBS, the rib cages were further 
incubated with hyaluronidase (2 mg/ml; Sigma) for 2 hours and hyaluronidase/collagenase D mixture (1 mg/ml, 
Roche) for 4 hours in DMEM at 37 °C. Undigested bony tissues were discarded by filtration, chondrocytes were 
collected by centrifugation and cultured in DMEM/F12 medium (1:1) (Invitrogen) supplemented with 10% of 
FBS, and 1% of ampicillin and streptomycin.
To immortalize primary chondrocytes, retrovirus expressing SV40 large T antigen were prepared from 293 T 
cells36,87 and used to infect chondrocytes (passage 1) overnight in the presence of 4 µg/ml polybrene. Infected cells 
were cultured for 48 hours and then selected with neomycin for 7 days. Neomycin-resistant clones were pooled, 
expanded, and used for this study. To knock down SHP2 expression in SOX9WT and SOX9cKO chondrocytes, ret-
rovirus expressing a control (SHP2WT) or short hairpin RNAi against murine SHP2 (SHP2KD) were prepared and 
used to infect SOX9WT and SOX9cKO chondrocytes as described previously36,88. Puromycin-resistant chondrocytes 
were selected, expanded and used for this study. To induce SOX9 deletion in vitro, SOX9WT and SOX9cKO chon-
drocytes were exposed to TM (1 µM) in the culture medium for 72 hours50. TM-treated chondrocytes were then 
used for biological and biochemical studies.
Antibodies and Reagents. Polyclonal antibodies against murine SHP2 and SOX9 were purchased from 
Santa Cruz and EMD Millipore, respectively. Monoclonal antibody against murine ERK2 was purchased from 
Santa Cruz. Alcian blue and Safranin O staining solutions were purchased from Poly Scientific.
Histology analysis and von Kossa staining. Femurs and tibias from control and SHP2 mutant mice were 
fixed in 4% formaldehyde for 3 days, decalcified, paraffin-embedded, and sectioned to stain with hematoxylin 
and eosin (H&E), alcian blue and Safranin O /fast green. To trace the fate of COL2α1- and COL10α1-expressing 
chondrocytes in vivo, femurs and tibias were collected from SHP2Col2α1ERCTR;R26mTG, SHP2Col2α1ERKO;R26mTG, 
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SHP2Col10α1CTR;R26mTG and SHP2Col10α1KO;R26mTG mice at the indicated time points and fixed in 4% formalde-
hyde overnight. Frozen sections were examined microscopically to visualize green (GFP) and red (RFP) fluores-
cent protein-positive cells. DAPI was used for nucleus counterstaining. All florescent and phase contrast images 
were taken using a Nikon digital fluorescence microscope and Aperio slide scanner (Vista, CA). Immunostaining 
was carried out using Vectorstain ImmPACT/DAB kit following the manufacture’s instruction. von Kossa stain-
ing was carried out using commercially-available kits, per the manufacturer’s instructions (Millipore).
In situ hybridization. Femors and tibias were collected from neonates at the indicated time points, fixed 
in 4% formaldehyde overnight, and then embedded in OCT compound. 10 µm frozen sections were cut using a 
cryostat for in situ hybridization with probes against murine Sox9, Acan, Col2α1, Col1α1, Ctnnb1, Ibsp, Runx2 
and Mmp13. Hybridization and detection of hybridization signals were achieved using RNAscope HD-Brown kit 
per the manufacture’s instruction (Advanced Cell Diagnostics).
Quantitative RT-PCR analyses. Total RNA was extracted from chondrocytes using RNeasy kit (Qiagen). 
cDNA was synthesized using 1 µg of total RNA with iScript™ cDNA Synthesis Kit (Bio-Rad) and qRT-PCR was 
performed with RT2SYBR® Green kit on a Bio-Rad CFX machine. All samples were normalized to Gapdh and 
Actin; gene expression was presented as fold increases or decreases compared with that of controls. All primer 
sequences used for this study are listed in the Supplementary Table 1.
µ-CT and X-ray radiograph analysis. X-ray imaging analysis of mice skeletons was done immediately 
after euthanasia using a digital radiography system (MX-20, Faxitron Bioptics, LLC, Tucson, AZ, USA). High 
resolution 3D volume images were generated using a desktop µ-CT40 system (Scanco Medical AG, CH) after 
fixation of bone specimens in 4% formaldehyde.
Western blot analysis. Cells were lysed into modified NP-40 lysis buffer (0.5% NP40, 150 mM NaCl, 1 mM 
EDTA, 50 mM Tris [pH 7.4]) supplemented with a protease inhibitor cocktail (1 mM PMSF, 10 mg/ml aprotinin, 
0.5 mg/ml antipain, and 0.5 mg/ml pepstatin)53. For immunoblotting, cell lysates (30–50 µg) were resolved by 
SDS-PAGE, transferred to PVDF membranes, and incubated with primary antibodies for 2 hours or overnight 
at 4 °C (according to the manufacturer’s instructions), followed by incubation with HRP-conjugated secondary 
antibodies (Bio-Rad).
Statistical analysis. Statistical differences between groups were evaluated by student t and x2 tests. A p value 
of <0.05 was considered to be significant. Analyses were performed by using Prism 3.0 (GraphPad, San Diego, 
CA) and Excel (Microsoft).
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